Liquid biopsies and those three little words: finding the perfect match for the MTB
Author:
Wahida Adam1ORCID, Buschhorn Lars2ORCID
Affiliation:
1. Institute of Metabolism and Cell Death Ingolstädter Landstraße 1 Neuherberg Germany 2. National Center for Tumor Diseases (NCT) Heidelberg Division of Gynaecological Oncology Im Neuenheimer Feld 440 Heidelberg Germany
Abstract
Abstract
Monitoring ctDNA by liquid biopsies seems to represent the perfect match for precision oncology and its cornerstone clinical framework: the molecular tumour board (MTB). Detecting and scrutinising the success of targeted therapies or tracking and, for that matter, addressing the therapy with the evolutive nature of a tumour are some of the main advancements one considers to be important for the MTB. One challenge is correlating the estimated allele frequency of each identified genetic alteration determined by analysing the ctDNA sequencing results and matching these with the range of suitable drugs, which may limit the simultaneous treatment of all tumour variations. This limitation arises because a new biopsy would typically be required to evaluate the response to treatment. As a result, evaluating the success of MTB recommendations relies on traditional staging methods, highlighting an existing diagnostic gap. Thus, optimising liquid biopsy technology could enhance the efficacy of MTB treatment recommendations and ensuing tailored therapies. Herein, we discuss the prospect of ctDNA analyses in the molecular tumour board.
Publisher
Walter de Gruyter GmbH
Subject
Genetics (clinical),Genetics
Reference26 articles.
1. Wahida, A., Buschhorn, L., Fröhling, S., Jost, P.J., Schneeweiss, A., Lichter, P., and Kurzrock, R. (2023). The coming decade in precision oncology: six riddles. Nat. Rev. Cancer 23, 43–54. 2. Tamborero, D., Dienstmann, R., Rachid, M.H., Boekel, J., Lopez-Fernandez, A., Jonsson, M., Razzak, A., Braña, I., De Petris, L., Yachnin, J., et al. (2022). The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer 3, 251–261. 3. Horak, P., Heining, C., Kreutzfeldt, S., Hutter, B., Mock, A., Hüllein, J., Fröhlich, M., Uhrig, S., Jahn, A., Rump, A., et al. (2021). Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. Cancer Discov. 11, 2780–2795. 4. van Tilburg, C.M., Pfaff, E., Pajtler, K.W., Langenberg, K.P.S., Fiesel, P., Jones, B.C., Balasubramanian, G.P., Stark, S., Johann, P.D., Blattner-Johnson, M., et al. (2021). The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discov. 11, 2764–2779. 5. Hlevnjak, M., Schulze, M., Elgaafary, S., Fremd, C., Michel, L., Beck, K., Pfütze, K., Richter, D., Wolf, S., Horak, P., et al. (2021). CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer. JCO Precis Oncol 5. 10.1200/PO.20.00248.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|